Antiagregating agents and anticoagulants
|
|
- Isabella McDowell
- 8 years ago
- Views:
Transcription
1 Antiagregating agents and anticoagulants
2 Causes of arterial thrombosis a) Unstable atherosclerotic plaque (crucial factor for arterial thrombosis) b) Endothelial dysfunction (more frequent - women middle age) c) Generalised hypercoagulaton For arterial thrombosis is decisive activation of thrombocyte homeostasis
3 Pathophysiology of acute coronary syndromes Soft plaque plaque disruption occlusive thrombus perfusion decrease ischemia necrosis
4 Venous thrombosis a) Blood velocity decreased (coagulation factors activaton) b) endothelial dysfunction c) generalized hypercoagulation For venous thrombosis is decisive secondary homeostasis activation
5 Antiplatelet therapy
6 TROMBOCYTE normal activation
7 ADHESION contact phase binding through vwf to subendothelial collagen trombocyte
8 ADHESION - stabilization phase binding through fibronectine, collagen, laminine and vwf subendothelial space trombocyte
9 THROMBOCYTE ADHESION
10 ACTIVATION - thrombocyte and ADP pathway (degranulation and GP IIb/IIIa receptor expresion). subendothelial space
11 ADHESION AND THROMBOCYTE AGREGATION bivalent proteins
12 Primary thrombus farmation and fibrin polymerization
13 ANTIPLATELET AGENTS 1) ADHESION BLOCKADE - GP Ib/IIa, vwf antagonists (clinical trials) 2) ACTIVATION BLOCKADE - inhibition - TXA 2., ADP, serotonine., thrombin activation (inhib. COX, TXA 2 recept., ticlopidin, clopidogrel) 3) PLATELET STABILISATION ( cyclic nukleotides) - camp (dipiridamol) or cgmp (NO donors) 4) ANTI-AGGREGATION (GP Iib/IIIa inhibition) - peptides (abciximab, eptifibatid), - fibans 1st. generation (tirofiban), 2. generation
14 Thromocyte adhesion, activation and aggregation ticlopidinc clopidogrel rec. ADP hrombine rec. heparine ridogrel thrombocyte rec. TXA2 ketanserin naftidrofuryl GPIb vwf collagen serotonine rec. GP Ia abciximab tirofiban eptifibatid IIb/IIIa IIb/IIIa vwf fibrinogen inhib. vwf IIb/IIIa IIb/IIIa Activation COX a TX synt. release TXA 2 ASA indobufen dazoxiben Vessel wall
15 Thromboxane activation inhibitors a) Cyclooxygenase inhibition (COX 1 ): - irreversible inhibition: ASA - reversible inhibition: indobufen, NSA, sulfinpyrazone b) Tromboxane syntase inhibition: dazoxibene, ozagrel c) TXA 2 receptors antagonists : ridogrel, nidrogrel
16 Acetylsalicylic acid (ASPIRIN, ASA) ireversible acetylation COX 1 (up to 7 days) farmacoeconomy highly effective optimal dose mg ( mg) 10-20% population ASA resistent indication: acute coronary ischemia (IM, unstable angina) secondary prevention (after IM, stroke, TIA, peripheral occlusion, arterial intervention) primary prevention high risk patients hypertension a diabetes
17 ASA mechanism of action Phospholipase - PLA2 trombocyte endothel COX-1 ASA indobufen arachidonic acid PGG 2 / PGH 2 COX-2 activated endothel COX-2 inhib. TXA 2 PGE 2 PGF 2a PGI 2
18 Cardiovascular mortality/morbidity decrease after ASA unstable angina 15 13,8% 10 8,3% 10,2% 5,8% placebo ASA myocardial infarction MI acute 14.4% 10.6% placebo ASA 11.7% 9.3% 5 3,5% 2,1% 5 2.2% 1.0% 0 0 CV events CV mortality nonfatal IM MI chronic placebo ASA CV events CV events nonfatal stroke stroke or TIA placebo ASA % % % % 8.1% 6.5% 4.7% % 6.3% 10.2% 6.6% 0 CV events CV mortality unstabile stroke 0 CV events CV mortality nonfatal stroke
19 ASA - CV MORTALITY AND MORBIDITY (IM, STROKE) (ANTIPLATELET TRIALIST COLLABORATION) STUDIES 3 primary prev. 20 cerebral 11 MI 11 AMI 12 AP 20 CABG/PTCA 28 peripheral 51 DVT 30 others 189 total Br Med J 1994 EVENTS COHORT ANTIPLATELET AGAINST CONTROL effect 2p < RRR ± SD 12 ± 6 % 24 ± 5 % 24 ± 4 % 26 ± 4 % 39 ± 9 % 33 ± 13 % 25 ± 10 % 42 ± 19 % 44 ± 10 % 25 ± 2 %
20 RESISTANCE TO ASA - antiaggegation effect decreased - multifactorial etiology - higher incidence of thrombotic events - 5% non-responders - 20% semi-responders
21 Competitive COX-1 inhibitors indobufen, sulfinpyrazon, Comparable effect to ASA not proven Not recomended for therapy
22 Thienopyridines O S N Cl ticlopidin (1. generation) S N C Cl clopidogrel (2. generation) O C H 3 C H 3 O O S O N F prasugrel (3. generation)
23 ADP activation inhibitors (thienopyridines) irreversibile block ADP activation More effective than ASA, Potenciation of ASA ticlopidine slow onset, agranulocytoses. clopidogrel faster onset, leukopenia rare potenciation of fibrinolysis indikations: acute coronary sy, sec. prevention., PTCA Very high price in comparison with ASA
24 TICLOPIDINE thienopyridine derivative, slow onset, full effect after 8-11 days Inhibition of ADP platelet activation (induced by collagen, adrenaline) ireversible effect for thrombocyte life span (effect disappears after days) dose 2x250 mg
25 TICLOPIDINE Indication: alergy or bad tolerance ASA CV events during ASA treatment PTCA, PTA (4 weels) Adverse events: GIT dyscomfort (with meal) neutropenia 0,5-1,0% (check blood count WBC!)
26 CLOPIDOGREL irreversible blockade platelet activation (and aggregation) mediated by ADP faster onset safer (rare neutropenia) dosage: 75 mg daily, first dose 300 mg, effect after 4-6 h., steady state after 3-7 d expensive
27 CLOPIDOGREL Effect - potentiation by ASA indications: acute coronary syndrome (up to 6-12 m after attack), coronary interventions (PTCA + stent, prim. PTCA) secundary prevention of atherosclerosis (not very effective) PTCA Percutaneous Transluminal Coronary Angioplasty
28 CV mortality (MI/stroke) changes after treatment with clopidogrel N:
29 ASA and clopidogrel secondary prevention- CV mortality/morbiditu (CAPRIE) stroke 7,3% MI - 3,7% Peripheral vascular disease 23,8% Total decrease 8,7% ASA better clopidogrel better
30 krevní průtok (% poklesu) ASA - clopidogresl combination - potentiation klopidogrel + ASA klopidogrel ASA placebo Herbert JM et al. Thromb Haemost 1998; 80: t (min.)
31 PRASUGREL thienopyridin ireversible block P2Y12 receptors Pro-drug metabolic activation resistance rare peroral, onset of actiity during 30 min faster onset.
32 PRASUGREL thienopyridin indications: acute coronary syndrome (up to 6-12 m after attack), coronary interventions (PTCA + stent, prim. PTCA) secundary prevention of atherosclerosis (not very effective)
33 příhody (%) Clopidogrel against prasugrelu mortality (12 měs.) CV+, IM, stroke clopidogrel prasugrel o 19% NNT = prasugrel bleeding clopidogrel dny NNH = 167
34 F Ticagrelor HO O N N N HN N N S F HO OH non-thienopyridine - P2Y 12 receptor block reversibile receptor inhibition peroral, quick onset (1-2 h) safer, but short acting very promissing for subacute treatment
35 10 Comparison of ADP receptor inhibitors acute CV events %* 19%* 16%* -20 CURRENT klopidogrel 75 vs 150 mg TRITON prasugrel PLATO ticagrelor
36 GPIIb/IIIa receptor antagonists
37 Mechanism of action GP IIb/IIIa antagonists
38 GP IIb/IIIa antagonists - accute coronary syndrome, including interventions (most effective) - economy more expensive (app US $) - peptides: abciximab (REOPRO) - antibodies eptifibatide (INTEGRILIN) - cyclic peptide - nonpeptide (fibans) 1. generation: parenteral - tirofibane (AGGRASTAT) peroral (orbo-, xemilo-, sibrafiban, ) 2. generation: higher affinity to receptors, other effects (roxi-, cromo-, frada-, lefradafiban)
39 GP IIb/IIIa inhibitors - mechanism of proagregating activity receptor conformational changes inactive active binding inhibitor fibrinogen GP IIb/IIIa GP IIb/IIIa site GP IIb/IIIa trombocyte
40 Abciximab (ReoPro) - Monoclonal antibody combination of 2 fragments - Specific binding to IIb/IIIa receptor - Long lastin effect (fading for 14 days) - High affinity to receptors Optimal effect for prevention and treatment of thrombotic complications after coronary interventions High price
41 small peptides IIb/IIIa peptide antagonists eptifibatid Imitate aminoacid sequention of fibrinogene chain (arginin-glycin-aspartin) Shorter effect in comparison with abciximab eptifibatid (cyclic heptapeptide) Main indication acute coronary events (nonq-mi) high risk patients
42 Non-peptide GP IIb/IIIa antagonists Tirofibane synthetic nucleoside analogue Injections Quick oncet of action Short acting - effect 4 8 hours Derived from Viper venom Indications non-stabile angina, PTCA
43 IIb/IIIa receptor antagonists clinical use PTCA Percutaneous Transluminal Coronary Angioplasty Acute coronary syndrom, mainly MI PTCA with thrombotic complicatons (local) Pharmacological treatment of non-q MI at risk patients Pharmacological treatment of AMI
44 NEW ANTIPLATELET AGENTS TRIFLUSAL (inhibition platelet COX), similar to ASA, better tolerability RIDOGREL (combination - block TXA 2 receptor and synthesis.), better than ASA (AMI) TROMBOSTATIN (oligopeptide, blocking thrombocyte thrombin receptor PAR-1, bradykinine degradating product), preclinical testing ANAGRELID - nonspecific inhibition of platelet activation (ADP, thrombin, collagen), for acute corronary syndrome only
45 Rational use of antiplatelet therapy Ischemic hearth disease acut form only (i.e. MI ) ASA, clopidogrel, eptifibatide, tirofiban (ticlopidine) Secondary prevention atherosclerosis after MI, stroke, TIA ASA, clopidogrel, event. ticlopidine) stable AP, silent ischemia, peripheral ischemia ASA, clopidogrel, event. ticlopidine Primary prevention of high risk patinets ASA After revascularisation interventions (stent) - ASA, clopidogrel, ticlopidine, abciximab, event. eptifibatid or tirofiban Atrial fibrilation (when anticoagulants are contraindicated) ASA
46 Anticoagulants
47 Secondary homeostasis erytrocytes trapping
48 coagulation system internal system external system XIa VIIa/TF ANTICOAGULATION IX IXa IX VIII VIIIa VIIIi VIIa/TF X Xa X V Va Vi act. protein C prot. S prot. C prothrombin thrombin XIII thrombomodulin fibrinogen fibrin fibrin net plazmin fibrin degradation product
49 ANTICOAGULANTS possibility for action thrombin inhib. - direct (hirudines, ximelagatran, agatroban, efegatran) - indirect (heparine, LMWH others) f. Xa inhibitors direct (xabans) - indirect (heparine, LMWH, pentasacharids - fondaparinux) 5) vitamine K dependent factors inhibition (vitamine K antagonists)
50 ANTICOAGULANTS mechanism of action 1. Thrombin inhibitors - direct /hirudines,ximelagatran, gatroban, efegatran) - indirect (heparines, LMWH) 2. Factor Xa inhibitors direct (xabans) - indirect (heparine, LMWH, pentasacharids - fondaparinux) 3. vitamin K dependent factors inhibition (vitamine K antagonists)
51 coagulation system internal system external system ANTICOAGULATION XIa VIIa/TF heparines, pentasacharides IX IXa IX VIII VIIIa VIIIi VIIa/TF i X Xa X V Va Vi act. protein C prot. S prot. C prothrombin htrombin XIII thrombomodulin fibrinogen fibrin fibrin net plazmin fibrin degradation product heparines, hirudins, ximelagatran
52 THROMBIN INHIBITORS a) indirect (heparine, LMWH) - no inhibition for thrombin bind to fibrin or f.xa b) direct (hirudines, competitive and noncompetitive inhibitors) - strong antithrombotic effect
53 INDIRECT THROMBIN INHIBITORS DIRECT TROMBIN INHIBITORS AT III TROMBIN Catalyt. site MELAGATRAN Reversible blockade of catalytic site THROMBIN LMWH, UFH ATIII mediated blockade of catalytic site for heparine activation HIRUDINE reversible blockade of fibrine catalytic and binding site THROMBIN
54 HEPARINE - UFH Sulphonyl-mucopolysacharide Continuous infusion necessary (sc. aplication uncertain) dosage prediction questionable (binding, variable farmacokinetic) Inability to inactivate thrombin bind to fibrin Neutralised by platelet factor 4 Induced trombocytopenie (HIT), bleeding Average effective dose 30 thousands IU 24h Neutralised by protamin sulfate Replaced in most indications by LMWH
55 Mechanism of action AT III Fibrinogen binding site THROMBN AT III catalytic site for f. Xa a thrombin TROMBIN f.xa UFH UFH, LMWH UFH LMWH AT III THROMBIN TROMBIN b i n d i n g AT AT III III AT III f.xa PENTASACHARIDS
56 Heparine fractionisation heparin (UFH) pentasacharids LMWH
57 Low molecular weight heparins (LMWH) Heparin depolymerisation (15 sacharides units) Higher inhibition fxa and lower thrombin (LMWH with longer chain higher trombin inhibition) Inability to inhibit thrombin bind to fibrin Longer effect Predictable effekt Good s.c. resorptione Lower incidence of trombocytopenie (HIT) Incomplete neutralization by protamine
58 Low molecular weight heparins (LMWH) mol.weight anti-xa/anti-iia UFH heparin Heparin ,0 dalteparin Fragmin ,7 enoxaparin Clexane ,8 nadroparin Fraxiparin ,6 parnaparin Fluxu ,7 reviparin Clivarin ,5 tinzaparin Logiparin ,9
59 % distribuce Diferences between LMWH sacharide iunits enoxaparin bemiparin reviparin parnaparin nadroparin dalteparin tinzaparin
60 PENTASACHARIDES - f.xa INHIBITORS selective factor Xa block, analog from pentasacharid sequence of heparinu, activate ATIII advatages: easy dosing, longer effect, predictable effect AT AT III III disadvantage: no antidote known AT III f.xa fondaparinux: prevention and treatment of perioperative TED and AKS better prophylaxisthan LMWH in DVT registered and reimbursed indaparinux: aplication 1x weekly
61 Hirudin, bivalirudin, lepirudin, desirudin direct trombin inhibitors reversibile blockade of the catalytic and binding side of fibrin proteins, parenteral aplication relat. shorter effect ( min) indication: heparin induced trombocytopenia - HIT (antibodies vs. compl. heparin and PF4) AKS, intervention (PTCA,..) DVT, pulmonary embolia TROMBIN
62 Hirudin, bivalirudin, lepirudin, desirudin hirudin natural protein Hirudo officinalis bivalirudin, lepirudin, desirudin analogs with better resorption, longer halflife and higer afinity to trombin High cost, practically rarely used metaanalysis show only not signif. lower mortality in AKS compared with standart therapy (ASA, LMWH)
63 Gatrans direct thrombin inhibitors
64 Dabigatran (Pradaxa) Direct binding to thrombin catalytic center without AT thrombin inhibition (free and even bind to fibrin) dabigatran fibrinová síť trombin katalyt. místo
65 Dabigatran Peroral (bioavailability of pro-drug 6%) Low variability response (not necessary monitoring of effect) Renal elimination Hepatic metabolism
66 Dabigatran Direct reversible thrombin inhibition peroral Quick onset (max. effect after 1 hour) Long lasting effect ( 2x daily) Indication: prevention and treatment TE comparable to LMWH For stroke prevention better than warafarin
67 kumulativní riziko Dabigatran vs warfarin atrial fibrialtion - thrombotic comlications (RELY) warfarin dabigatran 2x110 mg dabigatran 2x150 mg RR 0.91 (95% CI: ) p<0.001 (NI) p=0.34 (Sup) RRR 34% RR 0.66 (95% CI: ) p<0.001 (NI) p<0.001 (Sup) roky Connolly SJ., et al. NEJM
68 Ximelagatran oral prodrug with conversion to melagatran excellent resorption and bioavailability reversibile inhibitor of trombin 2x daily, without monitoring need lower variability compared to warfarin (less interactions) TROMBIN Indication: prevention anad FT treatment, longterm anticoagulation in TED prevention
69 Xabans direct inhibition of f. Xa rivaroxaban, apixaban, otamixaban, edoxaban,
70 Rivaroxaban (Xarelto) Reversible inhibition of f. Xa (even bind to fibrin) Direct effect without AT Strong inhibition of thrombin activaton, but not thrombin activity rivaroxaban f. Xa katalyt. místo
71 Rivaroxaban peroral t 1/2 6-9 hours, 1-2x daily Small variability in response Prevention of TE after ortopedic operations, atrial fibrilation, DVT treatment comparable to enoxaparine
72 incidence (%) Rivaroxaban enoxaparin hip operations TEN total RRR 70% TEN severe RRR 88% enoxaparin rivaroxaban TEN sympt. bleeding 0 3.7% 1.1% 2.0% 0.2% 0.5% 0.3% 0.1% 0.3%
73 kumulativní výskyt (%) Rivaroxaban vs warfarin atrial fibrilation stroke prevention rivaroxaban warfarin výskyt příhod warfarin 21% rivaroxaban HR (95% CI): 0,79 (0,66, 0,96 P-value Non-Inferiority: < Days Studie ROCKET AF
74 Apixaban direct f. Xa inhibition Peroral and injections Standard effect, no monitoring t 1/ hours, 1-2x daily Low risk of interactions
75 Apixaban For prevention of TE after ortopediv operatins better than enoxaparine For prevention of strojke during atrial fibrialtion better than ASA and warfarin
76 COAGULATION SYSTEM internal pathway external pathway ANTICOAGULATION SYSTEM XIa VIIa/TF heparin, pentasacharides IX IXa IX VIII VIIIa VIIIi VIIa/TF X Xa X V Va Vi akt. prot. C prot. S prot. C protrombin trombin XIII trombomodulin fibrinogen fibrin fibrin net plazmin degradation fibrin products heparin, hirudines,ximelagatran
77 vitamin K warfarin
78 Vitamin K antagonist- WARFARIN - Synthesis inhibition of vitamin K dependrnt factors (coagul. and anticoagul.) - Currentlythe only registered orally effective anticoagul. - good bioavailab., plasma protein binding - 5x effective stereoizomer metabol. CYP 2C9 - Signif. interindivid. variability metabol., interaction with food and other drugs, vit. K in food - Monitoring the (INR) effect is essential - First stage of treatment procoagul. effect (inhib. synt. anticoagul. factors), suuitable combination with LMWH
79 COAGULATION SYSTEM internal pathway external pathway ANTICOAGULATION SYSTEM XIa VIIa/TF IX IXa IX VIII VIIIa VIIIi VIIa/TF X Xa X V Va Vi act. prot. C prot. S prot. C protrombin trombin XIII trombomodulin fibrinogen fibrin fibrin net plasmin degradation fibrin products antivitamines K tpa
80 warfarin KUMATOX - jed na potkany a myši
81 CYP2C9 Polymorfism via CYP2C9 metabolism 15-20% of drugs - ASA and NSAIDs, warfarin, sulphonamides, phenitoin, barbiturates, - activation of AT 1 rec. blockers (sartanes) > 30 types of polymorfism: slow, medium and quick metabolism Impact of CYP2C9*2 (10-20% population) CYP2C9*3 (6-9% population) slow metabol. significanz slow down degradation of warfarin (5-27x clearence), risc of bleeding
82 poměr rizika Narrow therapeutic window warfarinu 15 rrisk trombembolisme terapeutic window Risk of bleeding INR INR < INR > 4.0
83 Warfarin indications Prevention of embolism Atrial fibrialtion Valvular prosthesis Chronic thromboembolis Pulnomal artery embolism Trombofilic disiease
84 Warfarin contraindications Coagulopathy, High risk of bleeding - Gastric ulcer Crohn disease, High hypertension gravidity
85 Bleeding during warfarin treatment WARFARIN Stop treatment vitamin K 1 p.o. (1-10 mg), event. i.v.. Fresh frozen plazma i.v. Prothromplex human coagulation factors II (prothrombin), VII, IX, X -?? Riziko krvácení po 7. dekádě, u jaterní či renální insuf., po iktu, při anamnéze krvácení, u diabetu,
86 Arterial trombosis treatment - fibrinolysis activation
87 FIBRINOLYSIS SCHEME Tissue-type (t-pa) plasmin Urokinase type (u-pa) activators plasminogen activators inhibitors PAI-1 PAI-2 PAI-3 plasminogen Plazmin inhibitors plasmin 2 -antiplasmin 2 -makroglobulin FIBRIN fibrin degradation products
88 Fibrin and fibrinolysis polymerisation scheme fibrinogen trombin faktor XIIIa Fibrin dimer fibrin polymer plasmin fibrin net Fibrin degradation products
89 Advantages and disadvantages of essential fibrinolytics streptokinases: effective, cost effective, antigenic, hypotension release r-tpa: quick and very effective, nonantigenic, select. short term effect, very expensive anistreplases: quick effect (bolus), long lasting (APSAC) antigenic, average price urokinases: effective, bolus, neantigenic, expensive
90 Fibrinolytics derivatives from t-pa (longer lasting effect, higher specificity to fibrin) alteplasis lanoteplasis TNK reteplasis
91 Trombolysis efect related to delay from onset of MI attack Reduced Mortality (%)
92
93 ANTI-PLATELET TREATMENT POSSIBILITIES 1) adhesis inhibitors: monocl. antibodies versus vwf and platelet rec.gpi 2) activation inhibitors: a) tromboxan activation blockers: COX blockers (ASA, indobufen) TX rec. inhibitors (ridogrel) tromboxan-synthasis inhibitor (dazoxiben) b) ADP rec. blockers: tiklopidin, klopidogrel c) serotonin rec. blockers: naftidrofuryl, ketanserin d) trombin rec. blocker: inhibitory trombinu e) multipotent platelet rec. blockers: (anagrelid) 3) agregation inhibitors: GPIIb/IIIa rec. antag. (abciximab, integrilin, epitifibatid, II. generation: roxifiban, lotrafiban, fradafiban) 4) platelet stabilisation : via camp (dipyridamol) or cgpm (NO donators)
Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD
Update on Antiplatelets and anticoagulants Timir Paul, MD, PhD Antiplatelets Indications Doses Long term use (beyond 12 months) ASA and combination use of NSAIDS ASA resistance Plavix resistance Plavix
More information3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.
To Clot or Not What s New In Anticoagulation? Anita Ralstin, MS CNS CNP 1 Clotting Cascade 2 Anticoagulant drug targets Heparin XI VIII IX V X VII LMWH II Warfarin Fibrin clot 1 Who Needs Anticoagulation
More informationTime of Offset of Action The Trial
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant Amgen Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What I am Talking About
More informationAnticoagulant therapy
Anticoagulation: The risks Anticoagulant therapy 1990 2002: 600 incidents reported 120 resulted in death of patient 92 deaths related to warfarin usage 28 reports related to heparin usage Incidents in
More informationAntiplatelet and Antithrombotics From clinical trials to guidelines
Antiplatelet and Antithrombotics From clinical trials to guidelines Ashraf Reda, MD, FESC Prof and head of Cardiology Dep. Menofiya University Preisedent of EGYBAC Chairman of WGLVR One of the big stories
More informationUse of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia
Use of Antithrombotic Agents In The Presence Of Neuraxial Anesthesia Insertion, removal or presence of a catheter in selected sites can place a patient who is antithrombotic agent at risk for a local bleeding
More informationAnticoagulation and Reversal
Anticoagulation and Reversal John Howard, PharmD, BCPS Clinical Pharmacist Internal Medicine Affiliate Associate Clinical Professor South Carolina College of Pharmacy Disclosures I have no Financial, Industry,
More informationBreaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice
Breaking Old Habits: Use of the New Oral Anticoagulants in Clinical Practice Antiplatelets and oral anticoagulants Aspirin Plavix Prasugrel Ticagrelor Apixaban Rivaroxaban Dabigatran- Direct thrombin inhibitor
More informationReversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services
Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know Ronald Walsh, MD Chief Medical Officer Community Blood Services HEMOSTATIC PROCESS Initiation and formation of the platelet plug
More informationNew Anticoagulants: What to Use What to Avoid
New Anticoagulants: What to Use What to Avoid Bruce Davidson, MD, MPH Clinical Professor of Medicine Pulmonary and Critical Care Medicine Division University of Washington School of Medicine Seattle USA
More informationMCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013. Anticoagulants
MCHENRY WESTERN LAKE COUNTY EMS SYSTEM OPTIONAL CE ADVANCED LEVEL (EMTP, PHRN, ECRN) August 2013 Anticoagulants Anticoagulants are agents that prevent the formation of blood clots. Before we can talk about
More informationTraditional anticoagulants
TEGH Family Practice Clinic Day April 4, 03 Use of Anticoagulants in 03: What s New (and What Isn t) Bill Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University
More informationThe author has no disclosures
Mary Bradbury, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Surgery September 18, 2012 Mary.bradbury@inova.org This presentation will discuss unlabeled and investigational use of products The author
More informationNew Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012
New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation Joy Wahawisan, Pharm.D., BCPS April 25, 2012 Stroke in Atrial Fibrillation % Stroke 1991;22:983. Age Range (years) CHADS 2 Risk
More informationLong term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial
Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial Camillo Autore Università di Roma Sapienza II Facoltà di Medicina e Chirurgia
More informationDisclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU
New Agents for Treatment of DVT Disclosure PI Adopt and Amplify trials Mark Oliver, MD, RVT, RPVI,FSVU BMS and Pfizer Speaker VTE Venous Thromboembolism Recognized DVT s New : 170,000 Recurrent : 90,000
More informationVenous Thrombo-Embolism (VTE) Therapy current challenges & opportunities
Venous Thrombo-Embolism (VTE) Therapy current challenges & opportunities Asher Winder M.D. Director, Department of Hematology Wolfson Medical Center כנס האיגוד הישראלי לפרמקולוגיה קלינית 2012 04-May-2012
More informationNew Anticoagulation Agents
New Anticoagulation Agents Use of New and Older Therapeutic Agents in the Treatment Regimen Michelle Geddes Case 1 40 year old woman with idiopathic proximal DVT. Previous heparin allergy (wheals, hives)
More informationWhat we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012
What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs Marvin A Wayne, MD, FACEP, FAAEM Associate Clinical Professor University of Washington, EMS Medical Director Whatcom County,
More informationAre there sufficient indications for switching to new anticoagulant agents
Are there sufficient indications for switching to new anticoagulant agents Meyer Michel Samama et Gregoris Gerotziafas Groupe Hémostase-Thrombose Hôtel-Dieu, Hôpital Tenon, Paris & Biomnis Ivry/seine,
More informationRR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) 3.75
ALL-CAUSE MORTALITY RR 0.88 (95% CI: 0.77 1.00) P=0.051 (superiority) Rate per year (%) 5.0 4.0 3.0 2.0 1.0 0 3.64 D150 mg BID 3.75 D110 mg BID RR 0.91 (95% CI: 0.80 1.03) P=0.13 (superiority) 4.13 Warfarin
More informationL'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy ISO 9001
L'aspirina è diventata obsoleta nell'era dei nuovi inbitori P2Y12? Leonardo Bolognese MD, FESC, FACC Cardiovascular Department, Arezzo, Italy Scientific Advances and Cardiovascular Mortality Nabel and
More informationNew anticoagulants: Monitoring or not Monitoring? Not Monitoring
The 2 nd World Congress on CONTROVERSIES IN HEMATOLOGY (COHEM) Barcelona, Spain September 6 8, 2012 New anticoagulants: Monitoring or not Monitoring? Not Monitoring Anna Falanga, MD Immunohematology and
More informationManagement of Patients on Anticoagulants. Haemostasis. Coagulation cascade. Cell-based model 19/11/2013
Management of Patients on Anticoagulants National Coal Mining Museum 11 Nov 2013 Navneet Lad StR Special Care Dentistry Aims: Discuss the different anti-platelet drugs available. Discuss the new generation
More informationTo aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.
UNFRACTIONATED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To aid practitioners in prescribing unfractionated heparin and low-molecular-weight
More informationNEW ANTIPLATELET AGENTS: An ideal platelet agent would have the following characteristics: 1. quick onset 2. reversible 3. benefit to patients 4.
NEW ANTIPLATELET AGENTS: An ideal platelet agent would have the following characteristics: 1. quick onset 2. reversible 3. benefit to patients 4. universal response 5. excellent safety profile 6. able
More informationAn#- Coagulant An#- Thrombo#c An#- Platelet Drugs
An#- Coagulant An#- Thrombo#c An#- Platelet Drugs 1 ANTICOAGULANT CLASSES INHIBITORS OF CLOTTING FACTOR SYNTHESIS WARFARIN (COUMADIN ) Rivaroxaban (Xarelto ) INHIBITORS OF THROMBIN HEPARIN, LEPIRUDIN (REFLUDAN
More informationDual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute
Dual Antiplatelet Therapy Stephen Monroe, MD FACC Chattanooga Heart Institute Scope of Talk Identify the antiplatelet drugs and their mechanisms of action Review dual antiplatelet therapy in: The medical
More informationGoals 6/6/2014. Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs. Ashkan Babaie, MD
Stroke Prevention in Atrial Fibrillation: New Oral Anti-Coagulants No More INRs Ashkan Babaie, MD Arrhythmia Service Providence Heart Clinic June 8 th, 2014 Goals Discuss the data behind approval of NOACs
More informationLaboratory Testing in Patients on Novel Oral Anticoagulants (NOACs)
Laboratory Testing in Patients on Novel Oral Anticoagulants (NOACs) Dr. Art Szkotak artur.szkotak@albertahealthservices.ca University of Alberta Hospital Edmonton, AB NOACs Direct Thrombin Inhibitors (DTI):
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationAntikoagulation und antithrombotische Therapie bei Herzerkrankungen
Antikoagulation und antithrombotische Therapie bei Herzerkrankungen Christian Sticherling Kardiologie Dimitrios Tsakiris Hämatologie Einsatz der Antikoagulation und antithrombotischen Therapie in der Kardiologie
More informationSession 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 3 of 4 Michael J. Sanfelippo, M.S. Technical Director, Coagulation Services Session 3 Topics Direct Thrombin Inhibitors:
More informationRivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012
Rivaroxaban A new oral anti-thrombotic Dr. Hisham Aboul-Enein Professor of Cardiology Benha University 12/1/2012 Agenda Ideal anticoagulant. Drawbacks of warfarin. Rivaroxaban in clinical trails. Present
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION. TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: ABBREVIATIONS: BACKGROUND:
STROKE PREVENTION IN ATRIAL FIBRILLATION TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention
More informationSTROKE PREVENTION IN ATRIAL FIBRILLATION
STROKE PREVENTION IN ATRIAL FIBRILLATION OBJECTIVE: To guide clinicians in the selection of antithrombotic therapy for the secondary prevention of ischemic stroke and arterial thromboembolism in patients
More informationNote: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.
INDEX Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Acquired bleeding disorders, 37-57 acquired combined inhibitor to factor V and thrombin, 55 acquired
More informationCritical Bleeding Reversal Protocol
Critical Bleeding Reversal Protocol Coagulopathy, either drug related or multifactorial, is a major contributing factor to bleeding related mortality in a variety of clinical settings. Standard therapy
More informationNew Approaches to, and Indications for, Antiplatelet Therapy
New Approaches to, and Indications for, Antiplatelet Therapy Kenneth A. Bauer, MD Professor of Medicine, Harvard Medical School Chief, Hematology Section, VA Boston Healthcare System Director, Thrombosis
More informationPer Morten Sandset p.m.sandset@medisin.uio.no. Hemostasis parameters and medication prior to radiological interventions
Per Morten Sandset p.m.sandset@medisin.uio.no Hemostasis parameters and medication prior to radiological interventions The challenge Familial or acquired defects in the hemostatic system that dispose for
More information4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285: 2864-71
Anticoagulation in the 21 st Century Adam Karpman, D.O. Saint Francis Medical Center/Oklahoma State University Medical Center Disclosures: None Atrial Fibrillation Most common arrhythmia in clinical practice.
More informationAntiplatelet and Antithrombotic Therapy. Dr Curry Grant Stroke Prevention Clinic Quinte Health Care
Antiplatelet and Antithrombotic Therapy Dr Curry Grant Stroke Prevention Clinic Quinte Health Care Disclosure of Potential for Conflict of Interest Dr. F.C. Grant Atrial Fibrillation FINANCIAL DISCLOSURE:
More informationCardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 Cardiology Medications Objectives The attendee will understand Indications,
More informationAnticoagulants in Atrial Fibrillation
Anticoagulants in Atrial Fibrillation Starting and Stopping Them Safely Carmine D Amico, D.O. Overview Learning objectives Introduction Basic concepts Treatment strategy & options Summary 1 Learning objectives
More information23/06/2014. Implications for the Gastroenterologist. No financial interests I am not a hematologist
Implications for the Gastroenterologist Dr. Daniel Sadowski Royal Alexandra Hospital Edmonton, Ab. No financial interests I am not a hematologist 65 y.o. male referred for iron deficiency anemia (FIT positive)
More informationNovel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations
Novel oral anticoagulant (NOAC) for stroke prevention in atrial fibrillation Special situations Dardo E. Ferrara MD Cardiac Electrophysiology North Cascade Cardiology PeaceHealth Medical Group Which anticoagulant
More informationXabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center
Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center DISCLOSURES No relevant financial disclosures I will
More informationNew Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013
New Treatments for Stroke Prevention in Atrial Fibrillation John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013 Classification Paroxysmal atrial fibrillation (AF) Last < 7
More informationAnticoagulation Therapy Update
Anticoagulation Therapy Update JUDY R. WALLING, FNP-BC ARRHYTHMIA MANAGEMENT MUSC CARDIOLOGY Outline Who do we anticoagulate? Review classes of Anticoagulants Review examples of Anticoagulants Review CHADS2
More informationXarelto (Rivaroxaban)
Xarelto (Rivaroxaban) Hightly selective, reversible, direct oral FXa inhibitor Maxium concentratiion after 2 to 4 hrs High bioavailability(66%),increase with food ( suggest with food) 1/3 from renal excretion,
More informationHot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke.
Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke. Favoriteplus.com www.heartrhythmcharity.org.uk www.forbes.com Victor J. Mazza, MD Assistant Professor of Medicine Cardiology,
More informationRivaroxaban for acute coronary syndromes
Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following
More informationThe speakers have attested that their presentation will be free of all commercial bias toward a specific company and its products.
Update on New Anticoagulants (Apixaban, Dabigatran and Rivaroxaban) Patient Safety Daniel B. DiCola, MD and Paul Ament,, Pharm.D Excela Heath, Latrobe, PA Disclosures: Paul Ament discloses that he receives
More informationANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head
ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY Dr. Mahesh Vakamudi Professor and Head Department of Anesthesiology, Critical Care and Pain Medicine Sri Ramachandra University INTRODUCTION
More informationNew Oral Anticoagulants. How safe are they outside the trials?
New Oral Anticoagulants How safe are they outside the trials? Objectives The need for anticoagulant therapy Indications for anticoagulation Traditional anticoagulant therapies Properties of new oral anticoagulants
More informationWhat s New in Stroke?
5 th McMaster University Review Course in INTERNAL MEDICINE What s New in Stroke? Robert Hart, M.D. HHS / McMaster Stroke Program Department of Medicine (Neurology) McMaster University Hamilton, Ontario
More informationOptimizing Anticoagulation Selection for Your Patient. C. Andrew Brian MD, FACC NCVH 2015
Optimizing Anticoagulation Selection for Your Patient C. Andrew Brian MD, FACC NCVH 2015 Who Needs to Be Anticoagulated and What is the Patient s Risk? 1. Atrial Fibrillation ( nonvalvular ) 2. What regimen
More informationWhat You Should NOAC About the New Anticoagulants. Dr Calum Young Cardiologist
What You Should NOAC About the New Anticoagulants Dr Calum Young Cardiologist Overview The Burden of AF What s Wrong With Warfarin? The Era of NOACs NOACs in New Zealand Clinical Trials with NOACs Potential
More informationPharmacology of Antiplatelet and Anticoagulants Agents
Pharmacology of Antiplatelet and Anticoagulants Agents 1 2 Antiplatelet Therapy: Common Oral Agents Acetylsalicylic acid (ASA) Clopidogrel bisulfate* Trade Name Aspirin Plavix Class Salicylate Thienopyridine
More informationThe Brave New (Anticoagulant) World
The Brave New (Anticoagulant) World Diane M. Birnbaumer, M.D., FACEP Emeritus Professor of Medicine University of California, Los Angeles Senior Clinical Educator Department of Emergency Medicine Harbor-UCLA
More informationAnticoagulation For Atrial Fibrillation
Anticoagulation For Atrial Fibrillation New Agents In A New Era Arjun V Gururaj, MD Arrhythmia and Electrophysiology Nevada Heart and Vascular Center Disclosures Biotronik Speaker Clinical investigator
More informationLupus anticoagulant Pocket card
Lupus anticoagulant Pocket card Issue number 5 2012 Antiphospholipid Syndrome 1 The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and /or pregnancy loss
More informationSpeaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014
Speaker Disclosure Matthew K. Pitlick, Pharm.D., BCPS St. Louis College of Pharmacy/VA St. Louis HCS mpitlick@stlcop.edu Matthew K. Pitlick, Pharm.D., BCPS declares no conflicts of interest, real or apparent,
More informationRivaroxaban (Xarelto ) by
Essentia Health Med Moment Short Video Tune-Up A brief overview of a new medication, or important new medication information Rivaroxaban (Xarelto ) by Richard Mullvain RPH BCPS (AQC) Current - August 2011
More informationDrugs that alter. blood coagulation. Brush up on your knowledge of these potentially life-saving drugs. By Amy M. Karch, RN, MS
PHARMACOLOGY REVIEW: Drugs that alter blood coagulation Brush up on your knowledge of these potentially life-saving drugs. By Amy M. Karch, RN, MS THE VASCULAR SYSTEM delivers oxygen and nutrients to all
More informationManaging Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting. Amy Huggins, BSN, RN
Managing Anticoagulants, Antiplatelets, and NSAIDS in the Interventional Radiology Setting Amy Huggins, BSN, RN Objectives 1 2 3 4 5 Recognize bleeding risk based on classes of IR procedures Differentiate
More informationCardiology Medications New Drugs, New Guidelines
Cardiology Medications New Drugs, New Guidelines Ken Kester, PharmD, JD Pharmacy Team Leader Nebraska Heart Hospital August 4, 2014 CARDIOLOGY MEDICATIONS Objectives The attendee will understand Indications,
More informationFinancial Disclosures. Learning Objectives 05/06/2015. None
ANTITHROMBOTIC MANAGEMENT PRE AND POST ENDOSCOPY Dustin Loomes, MD, FRCPC, Advanced training in Inflammatory Bowel Disease University of Alberta Hospital, Edmonton, AB St. Paul s Hospital, Vancouver, BC
More informationManagement for Deep Vein Thrombosis and New Agents
Management for Deep Vein Thrombosis and New Agents Mark Malesker, Pharm.D., FCCP, FCCP, FASHP, BCPS Professor of Pharmacy Practice and Medicine Creighton University 5 th Annual Creighton Cardiovascular
More informationAnticoagulation at the end of life. Rhona Maclean Rhona.maclean@sth.nhs.uk
Anticoagulation at the end of life Rhona Maclean Rhona.maclean@sth.nhs.uk Content Anticoagulant Therapies Indications for anticoagulation Venous thromboembolism (VTE) Atrial Fibrillation Mechnical Heart
More informationWOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast
WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION Van Crisco, MD, FACC, FSCAI First Coast Conflicts of Interest I have been a paid consultant and speaker for AstraZeneca, makers of
More informationAnalyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation Drew Baldwin, MD Virginia Mason Seattle, Washington NCVH May 29,
More informationTherapeutic Class Overview Oral Anticoagulants
Therapeutic Class Overview Oral Anticoagulants Therapeutic Class Overview/Summary: The oral anticoagulants, dabigatran etexilate mesylate (Pradaxa ), rivaroxaban (Xarelto ), and warfarin (Coumadin, Jantoven
More informationNew Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis. Mark Crowther
New Anticoagulants for the Treatment of Thromboembolism With a little subplot on superficial thrombophlebitis Mark Crowther 1 Disclosures Advisory Boards in last 24 months Pfizer, Alexion, Bayer, CSL Behring,
More informationEast Kent Prescribing Group
East Kent Prescribing Group Rivaroxaban (Xarelto ) Safety Information Approved by the East Kent Prescribing Group. Approved by: East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal
More informationxaban) Policy covered: Coverage of following criteria: the following those who meet the or Hip Xarelto is For those impacted by this policy.
Xarelto (rivarox xaban) Policy Number: 5.01.575 Origination: 06/2014 Last Review: 07/2015 Next Review: 07/2016 Policy BCBSKC will provide coverage for Xarelto when it is determined to be medically necessary
More informationAtrial Fibrillation: Stroke and Thromboprophylaxis. Derek Waller
Atrial Fibrillation: Stroke and Thromboprophylaxis Derek Waller Atrial Fibrillation in the Elderly: Risk of Stroke Framingham study AGE 50-59 60-69 70-79 80-89 Prevalence of AF % Attributable Risk of AF
More informationTHE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS
THE BENEFITS OF RIVAROXABAN (XARELTO ) ACROSS MULTIPLE INDICATIONS AND THE RELEVANCE TO CARDIOLOGISTS Ingo Ahrens, Christoph Bode Cardiology and Angiology I, Heart Center Freiburg University, Freiburg,
More informationComparison between New Oral Anticoagulants and Warfarin
Comparison between New Oral Anticoagulants and Warfarin Warfarin was the mainstay of oral anticoagulant therapy until the recent discovery of more precise targets for therapy. In recent years, several
More informationNew Anticoagulants: When and Why Should I Use Them? Disclosures
Winship Cancer Institute of Emory University New Anticoagulants: When and Why Should I Use Them? Christine L. Kempton, MD, MSc Associate Professor of Pediatrics and Hematology and Medical Oncology Hemophilia
More informationHow To Treat Aneuricaagulation
Speaker Introduction Jessica Wilhoite, PharmD, BCACP Doctor of Pharmacy: Purdue University Postgraduate Residency Training: PGY1 Pharmacy Practice St. Vincent Hospital PGY2 Ambulatory Care St. Vincent
More informationCilostazol versus Clopidogrel after Coronary Stenting
Cilostazol versus Clopidogrel after Coronary Stenting Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea AMC, 2004 Background
More informationAntithromboticthrombotic Monitoring
Introduction to Antithromboticthrombotic Monitoring 1 Topics What is thrombosis, and why is it significant? Coagulation Cascade Pathways of coagulation, anticoagulation, and fibrinolysis Thrombophilia
More informationNHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation
NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation Date of First Issue 06/06/2012 Approved 06/06/2012 Current Issue Date 29/10/2014 Review Date 29/10/2016 Version 1.4 EQIA Yes 01/06/2012
More informationManagement of atrial fibrillation. Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD
Management of atrial fibrillation Satchana Pumprueg, MD Sirin Apiyasawat, MD Thoranis Chantrarat, MD Antithrombotic therapy in atrial fibrillation Satchana Pumprueg, MD AF has serious consequences Independent
More informationEMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults. February, 2013
EMMC Guide on Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults February, 2013 1 Quick Index To Reversal Recommendations Anti-Platelet Medications Page P2Y12
More informationDevang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical
Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical Center A.Fib affects 2.2 million Americans. The lifetime
More informationCommittee Approval Date: September 12, 2014 Next Review Date: September 2015
Medication Policy Manual Policy No: dru361 Topic: Pradaxa, dabigatran Date of Origin: September 12, 2014 Committee Approval Date: September 12, 2014 Next Review Date: September 2015 Effective Date: November
More informationGuidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults
Guidelines for the Management of Anticoagulant and Anti-Platelet Agent Associated Bleeding Complications in Adults Purpose: To be used as a common tool for all practitioners involved in the care of patients
More information10/21/14. Coagulation and New Anticoagulants. Overview. Blood Composition
Coagulation and New Anticoagulants Maureen E. Mays, MD, MS, FACC Director ~ Portland Preventive Cardiology Diplomate, American Board of Clinical Lipidology www.portlandpreventivecardiology.com October
More informationLAMC Reversal Agent Guideline for Anticoagulants 2013. Time to resolution of hemostasis (hrs) Therapeutic Options
LAMC Reversal Agent Guideline for Anticoagulants 2013 Medication resolution of hemostasis (hrs) Intervention Administration Instructions Heparin 3-4 Protamine 1mg IV for every 100 units of heparin Slow
More informationAnticoagulation Essentials! Parenteral and Oral!
Anticoagulation Essentials! Parenteral and Oral! Anti-Xa and Anti-IIa! Parenteral Anticoagulants! Heparin family (indirect anti-xa and anti-iia):! UFH! LMWH (enoxaparin, fondaparinux)! Direct thrombin
More informationABOUT XARELTO CLINICAL STUDIES
ABOUT XARELTO CLINICAL STUDIES FAST FACTS Xarelto (rivaroxaban) is a novel, oral direct Factor Xa inhibitor. On September 30, 2008, the European Commission granted marketing approval for Xarelto for the
More informationSCRN Medication Review. Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center
SCRN Medication Review Susan M. Gaunt MS APRN ACNS-BC CCRN CNRN Gwinnett Medical Center Objectives To explain the indications, contraindications, interaction, timing, dosing, side effects of: Thrombolytics
More informationPlatelet Function analysis using Multiple Electrode Aggregometry (Multiplate )
Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate ) Multiplate platelet function analysis in whole blood based on impedance aggregometry Multiplate instrument 5 channels for
More informationLow Molecular Weight Heparin. All Wales Medicines Strategy Group (AWMSG) Recommendations and advice
Low Molecular Weight Heparin All Wales Medicines Strategy Group (AWMSG) Recommendations and advice Starting Point Low Molecular Weight Heparin (LMWH): Inhibits factor Xa and factor IIa (thrombin) Small
More informationDUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania
DUAL ANTIPLATELET THERAPY Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania DUAL ANTIPLATELET THERAPY (DAPT) Dual antiplatelet regimen
More informationThrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare
Thrombosis management: A time for change practical management with NOACs Dr Wala Elizabeth Medical Director, Bayer Healthcare Kenya Association of Physicians Conference 10 th May 2013 New anticoagulants:
More informationAntiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty
Round Table: Antithrombotic therapy beyond ACS Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty M. Matsagkas, MD, PhD, EBSQ-Vasc Associate Professor
More informationNOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology
NOAC s post Myocardial Infarction Peter Clemmensen MD, PhD, FESC, FSCAI Chief of Cardiology Department of Medicine Division of Cardiology Nykøbing F Hospital Denmark Disclosure of Conflict of Interest
More information